About
Partner with over two decades in CNS drug discovery and development, contributing to medicines such as Lexapro, Vyvanse and Zulresso. Previously CEO of ABIO-X and CEO/Chief Innovation Officer at Sage Therapeutics.
Experience
- Tortugas NeuroscieceChief Executive Officercurrent2026 β presentMassachusetts, United States
- Compass PathwaysDirectorcurrent2025 β presentUnited Kingdom
- Kenai TherapeuticsChairmancurrent2024 β presentUnited States
- Cure VenturesPartnercurrent2024 β present
- Noema PharmaChairman of the Boardcurrent2021 β present
- Karuna TherapeuticsDirector2015 β 2024
- Generation BioDirector2016 β 2024
- Sage TherapeuticsDirector2013 β 2023
- Sage TherapeuticsChief Executive Officer2013 β 2020Greater Boston Area
- ABio-XChief Executive Officer2022 β 2023
- Shire PharmaceuticalsPresident Shire Regenerative Medicine2012 β 2013
- Shire PharmaceuticalsSenior Vice President R&D - Specialty Pharma and Regenerative Medicine2011 β 2012
- Shire PharmaceuticalsSenior Vice President Research and Development2008 β 2011
- Isis PharmaceuticalsEVP2007 β 2008
- Forest LaboratoriesEVP/CMO2002 β 2007
- UpjohnChief Medical Officer/ VP Clinical Development1991 β 1996
Education
- Harvard Medical SchoolMD
- Amherst CollegeBA, Biology/English
- Harvard Medical School
Skills & more
IND2Clinical Development91Drug Development68Pharmaceutical Industry50Biotechnology44Clinical Trials38R&D37Biopharmaceuticals37Oncology21Neurology20Drug Discovery18Regulatory Affairs15
+12 more
Clinical ResearchRegulatory SubmissionsLifesciencesMedical DevicesFDACROInfectious DiseasesCross-functional Team LeadershipRegenerative MedicineCTMSNeuroscienceImmunologyFrom Jeffrey's professional profile.
Same school
Also attended Harvard Medical School113
Niko BonatsosInvestment Team at General CatalystAnthony PhilippakisInvestor at GV (Google Ventures)Ben RobbinsInvestor at GV (Google Ventures)David ReshefInvestor at GV (Google Ventures)Krishna YeshwantInvestor at GV (Google Ventures)Morgan CheathamPartner and Head of Healthcare and Life Sciences at Breyer Capital
+ 107 more
Shared employers
Also worked at Compass Pathways1
Also worked at Karuna Therapeutics1
Also worked at Generation Bio2
Also worked at Forest Laboratories5
Colleagues at Cure Ventures
Albert J. Robichaud
Partner at Cure Ventures
Annie Mitsak
Partner at Cure Ventures
Bill Amsbaugh
CTO and Partner at Cure Ventures
Courtney Turner
Director of Finance at Cure Ventures
David Fallace
Managing Partner at Cure Ventures
Dr. Michael Aberman
Investor at Cure Ventures
Dr. Milenko Cicmil
Investor at Cure Ventures
Drew King
CFO and Partner at Cure Ventures

.png)

























